Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,800
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,922.00 | 4.90 | 0.05% |
CAC 40 | 7,632.01 | 85.85 | 1.14% |
DAX 40 | 23,757.69 | 331.72 | 1.42% |
Dow JONES (US) | 44,144.62 | 556.04 | 1.28% |
FTSE 100 | 9,128.30 | 59.72 | 0.66% |
HKSE | 24,733.45 | 225.64 | 0.92% |
NASDAQ | 21,007.35 | 357.21 | 1.73% |
Nikkei 225 | 40,290.70 | 508.90 | -1.25% |
NZX 50 Index | 12,684.04 | 45.36 | -0.36% |
S&P 500 | 6,320.93 | 82.92 | 1.33% |
S&P/ASX 200 | 8,663.70 | 1.70 | 0.02% |
SSE Composite Index | 3,583.31 | 23.36 | 0.66% |